MGC Pharmaceuticals discuss their progress since listing and Alan Green on 3 Stocks

Justin Waite
Vox Markets Podcast with Justin Waite
14:07, 8th March 2021

AudioBoom Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here


On today's Vox Markets Podcast: MGC Pharmaceuticals discuss their progress since listing and Alan Green on 3 Stocks

Ron Lipsky VP of Business Development & International Relations at MGC Pharmaceuticals #MXC  FOLLOW discusses recent progress at the company after they became the first medicinal cannabis company to list on LSE a month ago.

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.


Alan Green CEO of Brand Communications talks about:

Smart Metering Systems #SMS FOLLOW

Logistics Development Group #LDG FOLLOW

Non-Fungible Tokens.

(Interview starts at 14 minutes 12 seconds)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
Login or register to post comments

Recent Articles
Watchlist